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study question: Is it possible to distinguish metabolically healthy polycystic ovary syndrome (MH-PCOS) from metabolically un-
healthy PCOS (MU-PCOS) by simple diagnostic tools such as body mass index (BMI), waist/hip ratio (WHR), at-risk category suggested
by Androgen Excess Society (AES) and visceral adiposity index (VAI)?
summary answer: VAI could be an easy and useful tool in clinical practice and in population studies for assessment of MU-PCOS.
what is known already: VAI is a good indicator of insulin sensitivity and cardiometabolic risk in oligo-ovulatory women with
PCOS.
study design, size, duration: We conducted a cross-sectional study of 232 women with PCOS in a university hospital setting.
participants/materials, setting, methods: Anthropometric, hormonal and metabolic parameters were evaluated. An
oral glucose tolerance test measured areas under the curve (AUC) for insulin (AUC2h insulin) and for glucose (AUC2h glucose). Homeostasis
model assessment of insulin resistance (HOMA2-IR), the Matsuda index of insulin sensitivity (ISI), the oral dispositional index (DIo) and VAI
were determined.
main results and the role of chance: The prevalence of MU-PCOS according to the different criteria was: BMI, 56.0%;
WHR, 18.1%; at-risk criteria of AES, 72.0% and VAI, 34.5%. The likelihood that a woman would exhibit MU-PCOS (except when diagnosed
by the WHR criterion) showed a signiﬁcant positive association with high HOMA2-IR [BMI criterion: (odds ratio (OR): 1.86; 95% conﬁdence
interval (CI): 1.43–2.41); risk criteria of AES (OR: 1.86; 95% CI: 1.36–2.56); VAI criterion (OR: 1.45; 95% CI: 1.17–1.80)] and a signiﬁcant
negative association with low ISI Matsuda [BMI criterion: (OR: 0.81; 95% CI: 0.72–0.91); risk criteria of AES (OR: 0.78; 95% CI: 0.69–0.89);
VAI criterion (OR: 0.82; 95% CI: 0.71–0.94)]. Only MU-PCOS according to the VAI criterion showed a signiﬁcant association with low DIo
(OR: 0.85; 95% CI: 0.75–0.96); these women also showed a signiﬁcant association with low luteal progesterone levels (OR: 0.97; 95% CI:
0.95–0.99).
limitations, reasons for caution: The analysis is limited by the lack of a gold standard deﬁnition of metabolic health that
would have allowed the execution of a receiver operator characteristic analysis of the four proposed criteria.
wider implications of the findings: The results will facilitate the early recognition of cardiometabolic risk in women with
PCOS before they develop overt metabolic syndrome.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine
disorder among women of reproductive age, with a prevalence of
between 5 and 10% (Diamanti-Kandarakis et al., 1999; Asuncion
et al., 2000). Recently, however, the variability in the prevalence
data was found to depend on the diagnostic criteria used; the preva-
lence reported being lower when the NIH criteria were used (March
et al., 2010) but higher reaching 19.9 and 15.3% using the Rotterdam
and Androgen Excess and Polycystic Ovary Syndrome Society criteria,
respectively (Yildiz et al., 2012)]. The prevalence of PCOS is also
linked to the body mass index (BMI) of the study population (Boyle
et al., 2012). In addition to chronic anovulation and hyperandrogenism
(clinical and biochemical), PCOS is also associated with an increased
risk of glucose intolerance and type 2 diabetes mellitus (DM), dyslipi-
demia, subclinical atherosclerosis and vascular dysfunction, independ-
ently of BMI (Dunaif, 1997). Although there are few large prospective
longitudinal studies of cardiovascular event rates and mortality in
PCOS, an increased prevalence of classical and non-classical cardiovas-
cular risk factors and changes in potential modulators of cardiometa-
bolic risk have been well documented (Amato et al., 2008; Galluzzo
et al., 2008; Hoffman and Ehrmann, 2008; Diamanti-Kandarakis and
Dunaif, 2012; Randeva et al., 2012). Today the inﬂuence of insulin re-
sistance (IR) in the genesis of PCOS and its associated cardiometabolic
risk are well known. Although in 2006 the Androgen Excess Society
(AES) declared that ‘PCOS should be ﬁrst considered a disorder of an-
drogen excess or hyperandrogenism’ (Azziz et al., 2006), it has recent-
ly issued a position statement highlighting the primary importance of
assessment of cardiometabolic risk and its prevention in women
with PCOS (Wild et al., 2010). In particular, considering the risk cat-
egories for women provided by the American Heart Association
(Mosca, 2007), the committee recommends that PCOS-related car-
diovascular disease (CVD) risk be categorized as follows: at-risk
[PCOS women with any of the following risk factors: obesity (especial-
ly increased abdominal adiposity), cigarette smoking, hypertension,
dyslipidemia (increased low-density lipoprotein (LDL)-cholesterol
and/or non-high-density lipoprotein (HDL) cholesterol), subclinical
vascular disease, impaired glucose tolerance (IGT), family history of
premature CVD (,55 years of age in male relative, ,65 years of
age in female relative)] or at high risk [PCOS women with metabolic
syndrome (MetS), type 2 diabetes, overt vascular or renal disease].
Given the frequent presence of IR in patients with PCOS and its asso-
ciation with adverse metabolic consequences, it is important to iden-
tify women with PCOS who are insulin resistant; regrettably, the gold
standard hyperinsulinemic euglycemic clamp and the minimal model
analysis of intravenous glucose tolerance test data, while being very re-
liable indexes (Bergman et al., 1985), involve high costs and difﬁculties
of execution, making them inapplicable in the routine diagnostic phase
of PCOS. For these reasons the use of a simple homeostatic model
assessment (HOMA-IR) has spread both in research and in clinical
practice (Matthews et al., 1985). However, this has considerable lim-
itations, especially in normal weight women with PCOS, where it is
unable to investigate the compensatory hyperinsulinism secondary
to IR (Fulghesu et al., 2006). A reasonable alternative is to use one
of the indexes derived from glucose and insulin values during the
oral glucose tolerance test (OGTT), which have proved to exhibit sat-
isfactory accuracy (Belﬁore et al., 1998; Mari et al., 2001); but given the
high prevalence of PCOS to run OGTTs on a sufﬁciently large scale
would entail considerable costs for the public health-care system.
In the current study, we wanted to verify whether it was possible to
distinguish women with metabolically healthy PCOS (MH-PCOS) from
women with metabolically unhealthy PCOS (MU-PCOS) through the
use of simple diagnostic tools such as BMI, waist to hip ratio
(WHR), the at-risk category suggested by AES (Wild et al., 2010)
and the visceral adiposity index (VAI) (Amato et al., 2010, 2011a,b).
Materials and Methods
Subjects
This study was approved by the Institutional Review Board at the Faculty
of Medicine of the University of Palermo. At the time of observation in our
outpatients clinic, all patients regularly signed an informed consent for the
scientiﬁc use of their data. It involved a cross-sectional study of 302 con-
secutive Caucasian women of reproductive age [mean: 24.09 years; stand-
ard deviation (SD): 6.03; range: 14–43] with mean BMI values of
29.68 kg/m2 (SD: 6.91; range: 18–50) followed up in our outpatients
clinic (from 1 January 2004 to 31 December 2011) for hirsutism and/or
other signs and symptoms of hyperandrogenism (acne/seborrhea, alope-
cia) and/or irregular cycles (oligo-amenorrhea). By applying the diagnostic
criteria of the AES (Azziz et al., 2006), we retrospectively selected 232 of
these cases (76.8%) with PCOS.
The following subjects were excluded from the study: women with
amenorrhea at the moment of observation (absence of vaginal bleeding
.6 months) as there were very few of these (22/302 cases) and those
with various progesterone (Pg) bleeding induction schemes, potentially
interfering with sex hormone patterns; women treated with clomiphene
citrate, oral contraceptives, antiandrogens and drugs to control their appe-
tite or insulin-sensitizing drugs (metformin, pioglitazone and rosiglitazone)
during the 6 months prior to the ﬁrst examination; women with hyperpro-
lact inemia (4/302 cases); patients with 17OH-progesterone (17OH-pg)
levels .6.05 nmol/l who, after 250 mg Synacthen (synthetic analog of
adrenocorticotrophic hormone), showed 17OH-pg .30.26 nmol/l at
60 min (3/302 cases); women with dehydroepiandrosterone sulfate
(DHEA-S) .16.32 mmol/l, who, when screened with a computerized
axial tomography scan, presented adrenal hyperplasia or adenoma or vir-
ilizing androgen-secreting neoplasias (1/302 cases); women whose clinical
and hormone evaluation (phenotype, increased 24 h free urinary cortisol,
high cortisol levels after 1 mg of overnight dexamethasone) suggested
Cushing’s syndrome (3/302 cases); all women with hypo- or hyperthy-
roidism were not taken into consideration for the study.
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The following relevant data were obtained from our database: possible
family history of diabetes, prematureCVD (,55 years of age inmale relative
and ,65 years of age in female relative), oligo-amenorrhea, hirsutism, acne
and age of menarche; weight, BMI, waist circumference (WC), blood pres-
sure and Ferriman–Gallwey (FG) score. It is routine practice in our outpati-
ents clinic to evaluate the degree of hirsutism with the use of the FG map
scoring system, which divides the body up into 11 domains. Hirsutism was
deﬁned as the FG score .8 (Ferriman and Gallwey, 1961). During the
follow-up in our outpatients clinic, patients were generally tested for FSH,
LH, 17-b-estradiol (E2), 17OH-pg, basal prolactin, total testosterone,
DHEA-S, D4androstenedione and sex hormone-binding globulin (SHBG),
during the follicular phase (Day 7 from the beginning of the last period).
On the same day, we also tested for total cholesterol, HDL cholesterol,
LDL cholesterol, triglycerides, glutamic–pyruvic transaminase (GPT),
glutamic-oxaloacetic transaminase (GOT) and uric acid and performed an
OGTT (75 g glucose) and measured glycemia and insulinemia at 0, 30, 60,
90 and 120 min. Serum Pg level was determined between Days 20 and 24
of the menstrual cycle and chronic oligo-anovulation was established if
two consecutive cycles were anovulatory [Pg level ,3 ng/ml (international
system (SI): ,9.54 nmol/l)] (Azziz et al., 2009). Biochemical hyperandro-
genismwas diagnosedwhen androgen levels were as follows: total testoster-
one .2.84 nmol/l, DHEA-S .12.14 mmol/l and D4androstenedione
.10.72 nmol/l [calculated on the basis of the 95th percentile upper limits
of basal serum androgen concentrations in 144 healthy normal Sicilian eume-
norrheal womenwithout hirsutism andwith no family history of PCOS (used
as a control group in a previous study (Amato et al., 2011a,b)]. Transvaginal
ovarian ultrasound scanningwas performedbetweenDays 5 and 10 from the
beginning of the last period using a 7.5-MHz vaginal probe transducer
(General Electric LOGIQ 400MD, Milwaukee, WI, USA). Both ovaries
were measured in the sagittal, transverse and coronal planes. Ovaries
were classiﬁed as polycystic if 12 or more follicles measuring 2–8 mm in
diameter were present in each ovary, and/or there was an increase in
ovarian volume (,10 ml) (Christensen et al., 1997; The Rotterdam
ESHRE/ASRM-sponsored PCOS Consensus Workshop Group, 2004;
Carmina et al., 2005).
MetS was diagnosed according to the National Cholesterol Education
Program Adult Treatment Panel (NCEP-ATP) III deﬁnition [Expert Panel
on Detection, Evaluation and Treatment of High Blood Cholesterol in
Adults, 2001] and diagnosis of DM according to the American Diabetes
Association criteria (Expert Committee on the Diagnosis and Classiﬁcation
of Diabetes Mellitus, 1997).
Assays
All hormonesweremeasured in our laboratory using commercial kits. These
included ELISA (DRG Diagnostics, DRG Instruments GmbH, Germany) for
FSH (mUI/ml), LH (mUI/ml), 17-b-E2 (pg/ml), 17OH-Pg (ng/ml), Pg (ng/
ml), PRL (ng/ml), total testosterone (ng/ml), D4androstenedione (ng/ml;
Arnika, Milan, Italy) and insulin (mUI/l; the intra- and inter-assay CVs
were ≤4% and ≤3.6%, respectively). Chemiluminescence assays were
used for DHEA-S (mg/dl; Immulite, Diagnostic Products, Genoa, Italy) and
serum SHBG (nmol/l; Immulite, Diagnostic Products, Genoa, Italy). Blood
glucose levels (mg/dl) weremeasured using an electrochemical system (Glu-
cocard, Menarini Diagnostics, Italy). Total cholesterol, HDL, triglycerides,
GOT, GPT and uric acid were measured in our laboratory using standard
assays. LDL cholesterol levels were calculated with Friedewald’s formula.
The conversion factors for the SI were the following: glucose (mg/dl
versus mmol/l: 0.0555), insulin (mUI/l versus pmol/l: 6.945), total choles-
terol (mg/dl versus mmol/l: 0.0259), total testosterone (ng/ml versus
nmol/l: 3.467), free testosterone (pg/ml versus pmol/l: 3.47), DHEA-S
(mg/dl versus mmol/l: 0.0272), D4androstenedione (ng/ml versus nmol/
l: 3.492), 17-b-E2 (pg/ml versus pmol/l: 3.671), 17-OHPg (ng/ml versus
nmol/l: 3.026), Pg (ng/ml versus nmol/l: 3.180), PRL (ng/ml versus mg/l:
1), FSH (mUI/ml versus IU/l: 1) and LH (mUI/ml versus IU/l: 1).
Free androgen index (FAI) was calculated as the ratio of total testoster-
one levels in nmol/l to SHBG levels in nmol/l × 100 (%) (Vermeulen
et al., 1999). Insulin sensitivity was estimated indirectly using fasting
plasma insulin and fasting plasma glucose to calculate the homeostatic
model of insulin resistance (HOMA2-IR) [calculations were performed
using free software provided by the University of Oxford Diabetes Trial
Unit (http://www.dtu.ox.ac.uk/homacalculator)] and using glucose and
insulin values during the OGTT to calculate the Matsuda index of insulin
sensitivity (ISI Matsuda) (Matsuda and De Fronzo, 2001) (10 000/
glucose (mg/dl) × insulin (mU/ml) × glucose mean × insulin mean). A
composite measure of b-cell function relative to insulin sensitivity,
assessed by oral disposition index (DIo) (Utzschneider et al., 2009), was
calculated as (DInsulin0–30/DGlucose0–30) × (1/fasting insulin). The trap-
ezoidal method was used for the calculation of the areas under the curves
for insulin (AUC2h insulin) and glucose (AUC2h glucose).
VAI was calculated as described previously (Amato et al., 2010) using
the following sex-speciﬁc equations, where TG is the triglyceride concen-
tration expressed in mmol/l and HDL is the HDL cholesterol concentra-
tion expressed in mmol/l:
Females: VAI = WC
36.58 = (1.89× BMI)
( )
× TG
0.81
( )
× 1.52
HDL
( )
.
Statistical methods
The Statistical Packages for Social Sciences SPSS version 17 and MedCalc
version 11.3 were used for data analysis. Baseline characteristics were
presented as the mean+ SD and range for continuous variables; rates
and proportions were calculated for categorical data. Normality of distri-
bution for quantitative data was assessed by the Kolmogorov–Smirnov
test. Because total cholesterol did not present normal distribution,
before statistical analysis with parametric tests, it was log-transformed. Dif-
ferences between two groups in univariate analysis were detected by the
unpaired Student’s t-test for continuous variables (after testing for equality
of variance: Levene test) and by the x2 test and Fisher’s exact test (when
appropriate) for categorical variables.
A case–control comparison was made between women with
MH-PCOS and MU-PCOS, distinguished using the following four criteria:
(i) BMI ≤ versus .27 kg/m2 [since some authors believe that this cutoff
identiﬁes IR (Garca-Este´vez et al., 2004; Stepto et al., 2013)], (ii)
WHR , versus ≥0.85 (http://whqlibdoc.who.int/publications/2011/
9789241501491_eng.pdf), (iii) the presence of metabolic risk as deﬁned
by 2010-AES Consensus Statement (Wild et al., 2010), (iv) VAI ≤
versus .1.675 [the cutoff point of VAI previously found to identify an
ISI Matsuda value of ,25th percentile in 144 healthy women (Amato
et al., 2011a,b)]. The agreement (Cohen’s kappa value) between the
four criteria was calculated. The kappa value ranges from 0 (full disagree-
ment) to 1 (full agreement). Values in the range of 0–0.20, 0.21–0.40,
0.41–0.60, 0.61–0.80 and 0.81–1.00 were considered poor, fair, moder-
ate, good and very good concordance (Altman, 1991).
A multiple logistic regression analysis was performed to determine the
association of MU-PCOS with hormonal and metabolic parameters. Vari-
ables signiﬁcantly associated with the dependent variable on univariate
analysis (probability threshold, P ≤ 0.050) were corrected for age and
AUC2h insulin (in the case of hormonal parameters), or for age and andro-
gen levels (in the case of metabolic parameters). HOMA2-IR, ISI Matsuda,
AUC2h insulin, AUC2h glucose and DIo were analyzed separately in the multi-
variate models, because they are collinear variables. A P value of ,0.05
was considered statistically signiﬁcant.
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Results
The demographic, clinical and biochemical characteristics (including
anthropometric measurements, hormonal proﬁle and metabolic
proﬁle) of the 232 PCOS women are presented in Table I. Of the
entire cohort of patients, only 28.4% had a normal weight and 1.3%
were underweight; the remaining women had a ponderal excess
(70.3%). Subdividing the 232 women with PCOS on the basis of the
four criteria described in the statistical methods, the prevalence of
MU-PCOS was 130/232 (56.03%) according to the BMI criterion,
42/232 (18.10%) according to the WHR criterion, 167/232
(71.98%) according to the risk criteria of AES and 80/232 (34.48%)
according to the VAI criteria. Agreement between the BMI criterion
and WHR, AES and VAI criteria was poor (K ¼ 0.152; P ¼ 0.001),
fair (K ¼ 0.354; P, 0.001) and fair (K ¼ 0.285; P, 0.001), respect-
ively; the agreement between the WHR and AES and VAI criteria
was poor (K ¼ 0.105; P ¼ 0.003) and poor (K ¼ 0.183; P ¼ 0.002),
respectively; the agreement between the AES and VAI criteria was
fair (K ¼ 0.204; P, 0.001).
MU-PCOS according to BMI > 27 kg/m2
Applying this criterion, women with MU-PCOS showed no phenotypic
differences from MH-PCOS, as regards oligo-menorrhea, polycystic
ovarian morphology (PCOM), hirsutism, biochemical hyperandrogen-
ism and acne/seborrhea (Table II). The MU-PCOS women showed a
signiﬁcantly higher age than the MH-PCOS ones (25.2+ 6.52 versus
23.0+5.16 years; P ¼ 0.006). The prevalence of MetS and of all its
......................................
........................................................................................
Table I Clinical, anthropometric and biochemical
characteristics of the 232 women with PCOS.
All PCOS women
(n5 232)
Mean+ SD Range
Age 24.2+6.05 14–43
BMI (kg/m2) 30.1+6.98 18–50
Age of menarche 12.0+1.39 9–17
WC (cm) 92+17.7 54–138
WHR 0.8+0.09 0.59–1.17
FG score 13.7+6.88 1–35
Classes of obesitya Subjects (No) Subjects (%)
Underweight 3 1.3
Normal weight 66 28.4
Overweight 64 27.6
Obese class I 42 18.1
Obese class II 37 15.9
Obese class III 20 8.6
Cigarette smoking 41 17.7
Dyslipidemia (increased LDL-C and/
or non-HDL-C)b
79 34.1
Subclinical vascular diseaseb 2 0.9
Family history of premature CVD
(,55 years of age in male relative,
,65 years of age in female relative)b
24 10.3
Metabolic syndromec 39 16.8
Diabetes or fasting glucose
≥5.6 mmol/l
35 15.1
High blood pressure (≥130/85
mmHg)
14 6
High triglycerides (≥1.7 mmol/l) 36 15.5
Low HDL cholesterol
(,1.04 mmol/l)
96 41.4
Increased WC (.88 cm) 127 54.7
IFG 28 12.1
IGT 9 3.9
IFG + IGT 5 2.2
DM 2 0.9
Hormonal proﬁles Mean+ SD Range
FSH (IU/l) 6.6+2.82 1–21.70
LH (IU/l) 8.5+4.58 0.30–24
17-b-E2 (pmol/l) 190+98. 8 30.95–587
17OH-pg (nmol/l) 4.4+2.94 0.51–20.58
Pg (nmol/l) 11.943+16.50 0.29–89.68
Total testosterone (nmol/l) 2.3+1.44 0.07–11.09
SHBG (nmol/l) 69+43.0 10–200
FAI [100 × (total testosterone/
SHBG)] (%)
5.4+6.05 0.18–42.49
DHEA-S (mmol/l) 8.1+4.52 1.33–23.61
D4androstenedione (nmol/l) 9.9+6.99 1.05–45.40
Metabolic proﬁles Mean+ SD Range
Continued
......................................
........................................................................................
Table I Continued
All PCOS women
(n5 232)
Mean+ SD Range
HOMA2-IR 2.3+1.35 0.40–7.20
ISI Matsuda 3.9+3.05 0.25–23.00
AUC2h insulin (pmol/l 120 min) 11 000+6800 762–36 540
AUC2h glucose (mmol/l 120 min) 770+151 477–1401
Dio 4.4+11.68 0.05–96.10
VAI 1.9+1.64 0.19–19.87
Total cholesterol (mmol/l) 5.2+1.20 2.94–11.56
HDL cholesterol (mmol/l) 1.3+0.28 0.17–2.19
Calculated LDL cholesterol
(mmol/l)
3.0+1.07 0.95–8.85
Non-HDL cholesterol (mmol/l) 3.9+1.22 1.60–10.58
Triglycerides (mmol/l) 1.29+0.56 0.29–4.35
Uric acid (mmol/l) 253+100.5 107.06–571
GOT (U/l) 21.2+7.81 11–68
GPT (U/l) 24.8+15.04 7–129
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; DM, diabetes
mellitus
aWHO classiﬁcation.
bAccording to the Consensus Statement by the Androgen Excess and PCOS
(AE-PCOS) Society (2010).
cAccording to the ATP III criteria.
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components was signiﬁcantly higher in the MU-PCOS women, while
there were no signiﬁcant differences for the categories of glucose tol-
erance except for a higher prevalence of impaired fasting glucose (IFG)
(Table II). A high-risk condition according to the AES deﬁnition was
more prevalent in MU-PCOS than in MH-PCOS (29.2 versus 2.9%;
P, 0.001). Multivariate logistic regression analyses showed that high
HOMA2-IR, AUC2h insulin, AUC2h glucose, VAI, triglycerides, GOT,
GPT, uric acid, low HDL cholesterol and ISI Matsuda were signiﬁcantly
associated with MU-PCOS. Multivariate analysis showed no associ-
ation between hormonal proﬁles and MU-PCOS (Supplementary
data, Table SI; Fig. 1).
MU-PCOS according to WHR ≥ 0.85
Women with MU-PCOS (identiﬁed by applying the WHR criterion)
showed no phenotypic differences compared with those with
MH-PCOS, as regards oligo-menorrhea, PCOM, hirsutism, biochem-
ical hyperandrogenism and acne/seborrhea (Table II). MU-PCOS
and MH-PCOS women had similar ages (23.7+ 5.95 versus 24.3+
6.08 years; P ¼ 0.525). The prevalence of MetS was signiﬁcantly
higher in women with MU-PCOS, but only a signiﬁcant increase in
the prevalence of the ‘high triglycerides’ and ‘increased WC’ compo-
nents was found; no signiﬁcant differences were found for the categor-
ies of glucose tolerance (Table II). A high-risk condition according to
the AES deﬁnition was more prevalent in MU-PCOS compared with
MH-PCOS (31.0% versus 14.7%; P ¼ 0.013). Multivariate logistic
regression analyses showed that high VAI, triglycerides and low HDL
cholesterol were signiﬁcantly associated with MU-PCOS. Multivariate
analysis showed no association between hormonal proﬁles and
MU-PCOS (Supplementary data, Table SI; Fig. 1).
MU-PCOS according to the presence of
metabolic risk as deﬁned by the 2010-AES
Consensus Statement
Applying this criterion, women with MU-PCOS showed no phenotypic
differences from ones with MH-PCOS, as regards oligo-menorrhea,
PCOM, hirsutism, biochemical hyperandrogenism and acne/sebor-
rhea (Table II). MU-PCOS women showed a comparable age to
MH-PCOS ones (24.5+6.40 versus 23.4+ 4.93 years; P ¼ 0.151).
The prevalence of MetS and of all its components (except the diabetes
or fasting glucose ≥5.6 mmol/l) was signiﬁcantly higher in MU-PCOS
women, while there were no signiﬁcant differences for the categories
of glucose tolerance (Table II). A high-risk condition according to the
AES deﬁnition was more prevalent in MU-PCOS compared with
MH-PCOS (24.0% versus 1.5%; P, 0.001). Multivariate logistic re-
gression analyses showed that the status of MU-PCOS has a signiﬁcant
positive association with HOMA2-IR, AUC2h insulin, VAI, total choles-
terol, LDL cholesterol, triglycerides, TGO, TGP, uric acid and a signiﬁ-
cant association negative with ISI Matsuda and HDL cholesterol.
Moreover women with MU-PCOS showed lower levels of SHBG
and higher levels of total testosterone and FAI (Supplementary data,
Table SII; Fig. 1).
MU-PCOS according to VAI >1.675
Applying this criterion, women with MU-PCOS showed phenotypic
differences from ones with MH-PCOS, meaning a higher prevalence
of oligo-menorrhea (88.8 versus 69.7%; P, 0.001) and hirsutism
(91.3 versus 72.4%; P, 0.001) (Table I). MU-PCOS women
showed a comparable age to MH-PCOS women (25.2+6.65
versus 23.7+ 5.66 years; P ¼ 0.083). The prevalence of MetS and
of all its components (except the diabetes or fasting glucose
≥5.6 mmol/l) was signiﬁcantly higher in MU-PCOS women, while
there were no signiﬁcant differences for the categories of glucose tol-
erance (Table II). A high-risk condition according to the AES deﬁnition
was more prevalent in MU-PCOS than in MH-PCOS (45.0 versus
3.3%; P, 0.001). Multivariate logistic regression analyses showed
that the status of MU-PCOS has a signiﬁcant positive association
with HOMA2-IR, AUC2h insulin, total cholesterol, LDL cholesterol,
uric acid and a signiﬁcant negative association with ISI Matsuda and
DIo. Regarding associations with hormonal proﬁles, women with
MU-PCOS showed no association with the androgenic quota, but
showed a signiﬁcant association with low Pg levels (Supplementary
data, Table SII; Fig. 1).
Phenotypes of PCOS according to AES
and MU-PCOS
According to the AES classiﬁcation of PCOS, nine different pheno-
types of the condition are possible (Supplementary data, Table SIII).
Using the different phenotypes described no signiﬁcant differences
are found in the prevalence of MU-PCOS, for all four of the used cri-
teria, except for the risk according to the AES criterion [signiﬁcant lower
prevalence of MU-PCOS in D phenotype (1.2 versus 9.2%; P ¼ 0.006)
and signiﬁcant higher prevalence of MU-PCOS in I phenotype (7.8
versus 0%; P ¼ 0.021) and VAI. 1.675 criterion [signiﬁcant lower
prevalence of MU-PCOS in H phenotype (2.5 versus 15.8%; P ¼
0.001) and in I phenotype (0 versus 8.6%; P ¼ 0.005)] (Supplementary
data, Table SIII).
Discussion
Insulin resistance is a common but not universal feature of PCOS, and
it is not always associated with an increased BMI. Indeed, many studies
have shown that both lean and obese women with PCOS have IR
(Dunaif, 1997); although, recently it has been shown that in PCOS
there is an intrinsic IR that is further worsened with increasing BMI
(Stepto et al., 2013). It is also known that obesity, in the general popu-
lation, is not necessarily an expression of cardiometabolic risk, given
that there exists ‘Metabolically Healthy Obesity’ in which the particu-
lar gynoid distribution of fat does not confer a cardiometabolic risk
(Despre´s, 2012).
Our study has proved that it is possible to identify the MU-PCOS
phenotype using simple and practical diagnostic tools. Women with
the MU-PCOS, beyond the criterion used to deﬁne them, showed a
high prevalence of MetS (risk according to AES: 22.8; WHR ≥ 0.85:
31%; BMI . 27 kg/m2: 27.7%; VAI . 1.675: 43.8%) and high preva-
lence of high risk according to AES (risk according to AES: 24.0%;
WHR ≥ 0.85: 31%; BMI . 27 kg/m2: 29.2%; VAI. 1.675: 45.0%).
The four criteria used showed fair-to-moderate agreement, except
that WHR ≥ 0.85 showed that a poor agreement with risk according
to AES and VAI . 1.675.
Among the four criteria VAI. 1.675, not only presented the
highest prevalence of MetS and high risk according to AES but identi-
ﬁed women with MU-PCOS that stood out from those with
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Table II Comparison of clinical characteristics between MH-PCOS and MU-PCOS, according to four different approaches [BMI > 27 kg/m2, WHR ≥0.85,
presence of cardiovascular risk according to the 2010-AES Consensus Statement, VAI >1.675 (cutoff point able to identify in 144 healthy women an ISI Matsuda
value of <25th percentile)].
BMI > 27 kg/m2 WHR ≥ 0.85 Risk according to AESa VAI > 1.675
MH-PCOS
(No 102)
MU-PCOS
(No 130)
MH-PCOS
(No 190)
MU-PCOS
(No 42)
MH-PCOS
(No 65)
MU-PCOS
(No 167)
MH-PCOS
(No 152)
MU-PCOS
(No 80)
Mean+ SD Mean+ SD P Mean+ SD Mean+ SD P Mean+ SD Mean+ SD P Mean+ SD Mean+ SD P
Age (years) 23.0+5.16 25.2+6.52 0.006 24.3+6.08 23.7+5.95 0.525 23.4+4.93 24.5+6.40 0.151 23.7+5.66 25.2+6.65 0.083
BMI (kg/m2) 23.8+2.59 34.9+5.25 ,0.001 29.4+7.10 32.9+5.70 0.004 25.0+3.08 32.0+7.11 ,0.001 28.4+6.72 33.3+6.36 ,0.001
Age of menarche
(years)
12.2+1.41 11.8+1.35 0.017 12.0+1.38 112.0+1.46 0.944 12.2+1.24 11.9+1.44 ,0.001 12.1+1.49 11.8+1.19 0.205
WC (cm) 76.6+9.76 104+12.5 ,0.001 89.5+17.57 103+13.8 ,0.001 80.2+10.25 96.5+17.88 ,0.001 86.6+16.60 102+5.3 ,0.001
FG score 12.6+6.36 14.5+7.18 0.032 13.8+6.94 13.2+6.70 0.611 12.8+6.57 14.0+6.99 0.222 13.2+6.87 14.6+6.86 0.152
Subjects (%) Subjects (%) P Subjects (%) Subjects (%) P Subjects (%) Subjects (%) P Subjects (%) Subjects (%) P
Diagnostic criteria of PCOSb
Oligo-menorrhea 77 (75.5) 100 (76.9) 0.799 141 (74.2) 36 (85.7) 0.113 51 (78.5) 126 (75.4) 0.628 106 (69.7) 71 (88.8) 0.001
PCOM 80 (78.4) 94 (72.3) 0.285 142 (74.7) 32 (76.2) 0.844 51 (78.5) 123 (73.65) 0.554 115 (75.7) 59 (73.8) 0.750
Hirsutism 78 (76.5) 105 (80.8) 0.426 150 (78.9) 33 (78.6) 0.957 50 (76.9) 133 (79.6) 0.649 110 (72.4) 73 (91.3) 0.001
Biochemical
hyperandrogenism
57 (55.9) 65 (50.0) 0.373 102 (53.7) 20 (47.6) 0.476 32 (49.2) 90 (53.9) 0.523 78 (51.3) 44 (55.0) 0.593
Acne/seborrhea 46 (45.1) 54 (41.5) 0.587 84 (44.2) 18 (42.9) 0.873 33 (50.8) 69 (41.3) 0.193 72 (47.4) 30 (37.5) 0.150
Chronic
oligo-anovulatione
69 (67.6) 87 (66.9) 0.907 128 (69.2) 26 (65.0) 0.605 42 (65.6) 112 (69.6) 0.566 100 (69) 54 (67.5) 0.821
Metabolic syndromec
(according to
NCEP-ATP III
criteria)
3 (2.9) 36 (27.7) ,0.001 26 (13.7) 13 (31.0) 0.007 1 (1.5) 38 (22.8) ,0.001 4 (2.6) 35(43.8) ,0.001
Diabetes or fasting
glucose ≥5.6 mmol/l
6 (5.9) 24 (18.5) 0.005 25 (13.2) 5 (11.9) 0.827 5 (7.7) 25 (15.0) 0.138 17 (11.2) 13 (16.3) 0.274
High blood
pressure
— 14 (10.8) ,0.001 12 (6.3) 2 (4.8) 1 — 14 (8.4) 0.016 4 (2.6) 10 (12.5) 0.006
High triglycerides 8 (7.8) 28 (21.5) ,0.001 21 (11.1) 15 (35.7) ,0.001 3 (4.6) 33 (19.8) 0.004 — 36 (45.0) ,0.001
Low HDL
cholesterol
25 (24.5) 71 (54.6) ,0.001 76 (40) 20 (47.6) 0.364 15 (23.1) 81 (48.5) ,0.001 35 (23.0) 61 (76.3) ,0.001
Increased WC 13 (12.7) 114 (87.7) ,0.001 92 (48.4) 35 (83.3) ,0.001 16 (24.6) 111 (66.5) ,0.001 61 (40.1) 66 (82.5) ,0.001
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MH-PCOS by having a higher prevalence of oligo-menorrhea and hir-
sutism. However, a signiﬁcant association between MU-PCOS and the
hormonal proﬁle was not observed, except with the low Pg levels in
the luteal phase. These data are supported by other studies
showing that patients with PCOS and oligo-menorrhea/amenorrhea
had more severe IR and a worse metabolic proﬁle than patients
with PCOS and regular cycles (Robinson et al., 1993; Welt et al.,
2006; Norman et al., 2007; Goodarzi et al., 2011; Panidis et al.,
2012). Moreover, our previous study (Amato et al., 2011a,b) found
that the oligo-menorrhoic phenotypes of PCOS (applying the Rotter-
dam criteria) are characterized by a high VAI and a condition of cardi-
ometabolic risk. More difﬁcult to interpret is the fact that women with
PCOS and VAI. 1.675, despite exhibiting a signiﬁcant increase in the
prevalence of hirsutism, do not show an increased androgen levels.
We may hypothesize that the insulin/IGF system plays a role in stimu-
lating hair follicle growth acting together with androgens and so the
increased responsiveness of the pilo-sebaceous unit to androgens
seems to be inﬂuenced by IR or compensatory hyperinsulinism (Phil-
pott et al., 1994; Itami et al., 1995; Su et al., 1999; Amato et al., 2006).
Three of the four criteria examined (BMI. 27 kg/m2, risk according
to AES and VAI. 1.675) showed a good association with metabolic
parameters (insulin sensitivity, insulin secretion, lipid pattern, transamin-
ase and uric acid), but only VAI. 1.675was signiﬁcantly associatedwith
a reduction in insulin secretion related to insulin sensitivity expressed
by DIo. However, while the risk according to the AES criterion highlights
the association with hyperandrogenemia, the VAI. 1.675 criterion
highlights the association with a luteal phase defect (low Pg). In our
opinion, the risk according to AES criterion, despite being a good criterion
in identifyingwomenwithMU-PCOS, is a very broad criterion (presence
of any of the following risk factors: obesity, cigarette smoking, hyperten-
sion, dyslipidemia, subclinical vascular disease, IGT, family history of pre-
matureCVD) and thereforemay tend to overestimate the prevalence of
MU-PCOS (71.9%with risk according to the AES criterion and 34.8%with
VAI. 1.675 criterion). In addition, some of the risk factors provided for
AES, though important cardiovascular risk factors do not play any role in
the pathogenesis of PCOS. VAI being an index of impaired fat distribu-
tion and function, in addition to indirectly expressing altered production,
release and/or function of adipocytokines and inﬂammatory factors,
involved in the genesis of PCOS (Gambineri et al., 2002), also expresses
a condition of cardiometabolic risk (Amato et al., 2010, 2011a,b).
As is well known, when applying the AES-PCOS criteria, nine differ-
ent phenotypes of the condition are possible. As conﬁrmed by other
literature data (Cupisti et al., 2011), our study showed that using the
different phenotypes described in the AES classiﬁcation there is no
advantage in identifying women with metabolic risk proﬁle.
A strong correlation between VAI and rate of peripheral glucose
utilization (M value) has also been demonstrated in the general popu-
lation during the gold standard euglycemic–hyperinsulinemic clamp
(Amato et al., 2010). Recently, this aspect has been addressed in a
population of young women with PCOS, in which the VAI can
replace visceral computed tomography scanning as a marker for
visceral adiposity and predicting IR (Oh et al., 2012).
Among the four criteria tested, VAI. 1.675 was the only one that
showed a signiﬁcant association between MU-PCOS and a reduction
in DIo. This is a very interesting datum, because if we consider the
low prevalence of diabetes (0.9%) and prediabetes (IFG: 12.1%, IGT
3.9%, IFG + IGT: 2.2%) in the 232 studied women, mainly due to
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the young age of patients, DIo could provide interesting data on the
diabetes risk linked to the condition of MU-PCOS. Indeed, DIo,
which expresses the ability of b-cells to adequately compensate IR
through increased insulin secretion, has been shown to predict the de-
velopment of diabetes in adults (Utzschneider et al., 2009).
In conclusion, risk according to AES, BMI . 27 kg/m2 and VAI .
1.675 have similar diagnostic value in detecting adverse metabolic
proﬁle in PCOS patients (MU-PCOS), although we believe that the
risk according to AES and BMI . 27 kg/m2 criteria tends to overesti-
mate the problem; given the simplicity of WC and BMI measurement
and TG and HDL assessment, we suggest that VAI could be an easy
and useful tool for the assessment of MU-PCOS in daily clinical prac-
tice and in population studies for the assessment of cardiometabolic
risk associated with PCOS and for taking appropriate preventive and
therapeutic measures. This interesting data, however, need further
conﬁrmation by appropriate prospective studies.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.
org/.
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